Events, Appointments, Approvals, Recommendations, and Agreements - Research Report on Elan, Alkermes, Hospira, pSivida, and Kindred PR Newswire NEW YORK, October 4, 2013 NEW YORK, October 4, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting Elan Corporation, plc (NYSE: ELN), Alkermes plc (NASDAQ: ALKS), Hospira Inc. (NYSE: HSP), pSivida Corp. (NASDAQ: PSDV), and Kindred Healthcare Inc. (NYSE: KND). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Elan Corporation, plc Research Report On September 30, 2013, Elan Corporation plc (Elan) announced that it has scheduled shareholder meetings for Monday, November 18, 2013 in connection with Perrigo Company's (Perrigo) proposed acquisition of Elan. According to the Company, the Company will host two special meetings of Elan shareholders on November 18, 2013 at The DoubleTree by Hilton Hotel Dublin, Burlington Road, Upper Leeson Street, Dublin 4, Ireland. Elan reported that the first meeting, which is convened by order of the Irish High Court, will be held at 10:00 a.m. (Irish time), and will be followed by an extraordinary general meeting of Elan shareholders. The Company also reported that the holders of ordinary shares as at 5:00 p.m. (Irish time) on November 16, 2013 will be entitled to attend and vote at the special meetings. Elan stated that holders and beneficial owners of American Depositary Shares (ADSs) as at 5:00 p.m. (New York City time) on October 11, 2013 (ADS Voting Record Date) will have the opportunity to instruct the ADS Depositary to vote the shares represented by ADSs that they hold as of the ADS Voting Record Date. The Company expects to mail the Scheme Circular and meeting materials to its shareholders by no later than October 17, 2013. The Full Research Report on Elan Corporation, plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/e996_ELN] -- Alkermes plc Research Report On September 30, 2013, Alkermes plc (Alkermes) announced the appointments to its senior management team. Alkermes appointed Srdjan (Serge) Stankovic, M.D., MSPH, as Senior Vice President of Clinical Development and Medical Affairs, and Peter Norman as Vice President of Government Affairs and Policy. Richard Pops, CEO of Alkermes, commented, "As our portfolio of new medicines expands, we are responding by strengthening our capabilities in two areas critical for our future: global clinical development and government affairs." The Full Research Report on Alkermes plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/e2f3_ALKS] -- Hospira Inc. Research Report On September 10, 2013, Hospira Inc. (Hospira) announced that the European Commission (EC)approved Inflectra (infliximab), Europe's first biosimilar monoclonal antibody (mAb) therapy. According to Hospira, Inflectra has been approved for the treatment of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis, Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA), and psoriasis. Dr. Stan Bukofzer, Corporate Vice President and Chief Medical Officer, Hospira, stated, "The rigorous scientific review and approval process by the EMA and EC confirms that Inflectra has demonstrated similar quality, efficacy and safety to Remicade. For over a decade biologic medicines have been pivotal in treating a range of inflammatory conditions, so the granting of marketing authorisation in Europe is a major milestone for Inflectra, and for the future of biologic therapy." The Full Research Report on Hospira Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/1f43_HSP] -- pSivida Corp. Research Report On September 30, 2013, pSivida Corp. (pSivida) announced that the United Kingdom's National Institute for Health and Care Excellence (NICE) issued final draft guidance recommending ILUVIEN as an option for the treatment of chronic diabetic macular edema (DME) that is insufficiently responsive to available therapies in pseudophakic eyes - those that have already undergone cataract surgery. pSivida reported that the recommendation reverses the final draft guidance previously issued by NICE with respect to this subgroup of chronic DME patients. Dr. Paul Ashton, President and CEO of pSivida said, "We are encouraged that Alimera plans to continue to work with NICE in an effort to broaden access to ILUVIEN to include all chronic DME patients who could benefit from the treatment." The Full Research Report on pSivida Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/d4eb_PSDV] -- Kindred Healthcare Inc. Research Report On October 1, 2013, Kindred Healthcare Inc. (Kindred) announced it has entered into agreements to renew early its leases with Ventas, Inc. (Ventas) for 22 transitional care (TC) hospitals (certified as long-term acute care hospitals) and 26 nursing and rehabilitation centers (collectively, the Renewal Facilities). Kindred reported that the current lease term for the Renewal Facilities was scheduled to expire in April 2015. According to the Company, the current aggregate annual rent for the Renewal Facilities approximates $79 million. Paul J. Diaz, CEO of Kindred, remarked, "We are pleased to have negotiated a mutually beneficial transaction with Ventas that accelerates our strategic repositioning plan in 2014 and paves the way for us to grow and advance our Integrated Care Market development plans. This transaction will be slightly accretive to Kindred's earnings in 2014 and will allow us to retain all of our TC hospitals that are up for renewal, along with several high quality nursing and rehabilitation centers. These transactions reflect another step in our maturing and improving relationship with Ventas and allow both companies to focus on the future and the creation of value for our patients and shareholders." The Full Research Report on Kindred Healthcare Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/ab58_KND] ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. SOURCE Analysts' Corner Contact: Joe Thomas: +1-310-496-8071 (North America)
Events, Appointments, Approvals, Recommendations, and Agreements - Research Report on Elan, Alkermes, Hospira, pSivida, and
Press spacebar to pause and continue. Press esc to stop.